Translations

Translations Policy


The purpose of our translation policy is to ensure that the translation of any document (i.e., Statement, explanatory paper, checklist, flow diagram or any of these documents for a original extension) accurately reflects the collaborative expertise of the original group. The EQUATOR Group only fully endorses "official" translations of the documents which have followed our translation policy.


Official translations must meet the following criteria:
  • Developed using one of the first publications of the most up-to-date version of the original document;

  • Developed in collaboration with the original group;

  • Follows the steps of translation described below;

  • If the translation is published, original authors will maintain primary authorship and translators will follow the authorship policy of the journal.

Steps of Translation:
  • Step 1: Establish contact with the original group and select which document you wish to translate: Statement, Explanatory paper, Checklist, Flow diagram or any of these documents for a original extension.

  • Step 2: Complete a draft of the translation of selected document (use most up-to-date document found on the official website).

  • Step 3: Have a back-translation of the draft translation carried out by an independent source. The person who back-translates the translated draft should not be involved with the translation in the first place and should be familiar with scientific language in both English and the selected language. If you do not know someone is able to carry out this task, please let us know and we will try to assist you in finding someone to do this.

  • Step 4: Send back-translated documents to the original group for review. We will make note of any differences between the back-translation and the original English publication and send you this feedback. (Please note: it is important that the translation be as close to the original English version as possible since the wording of the document was carefully and purposefully selected by the original group based on a consensus process.)

  • Step 5: If necessary, revise translated document based on feedback from the original group. This step may entail one or more iterations to ensure that wording of the translation is as accurate as possible.

  • Step 6: Disseminate the completed translation. While the translation will be posted to the EQUATOR website for users of the selected language to access freely, we encourage translators to seek publication of their translation in an open-access journal. While the original authors will retain primary authorship on the translated document, translators will be listed in the acknowledgments section of the article as well as on secondary author byline where permitted by journals (i.e. under the author line state “Translated by xxx”). Translators are encouraged to write an accompanying editorial which may be done in collaboration with one or more original executive, if desired. All official translations of the original will be announced and posted on the EQUATOR website.

Translated reporting guidelines:
  1. David Moher, Sally Hopewell, Kenneth F Schulz, Victor Montori, Peter C G tzsche, P J Devereaux, Diana Elbourne, Matthias Egger, Douglas G Altman, 周庆辉, 卞兆祥, 刘建平. CONSORT 2010说明与详述：报告平行对照随机临床试验指南的更新[J]. 中西医结合学报, 2010, 8(08): 701-741.

  2. David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G. Altman, The PRISMA Group. 系统综述和荟萃分析优先报告的条目：PRISMA声明[J]. 中西医结合学报, 2009, 7(09): 889-896.

  3. Erik von Elm, Douglas G Altman, Matthias Egger, Stuart J Pocock, Peter C G tzsche, Jan P Vandenbroucke, for the STROBE initiative. 加强流行病学中观察性研究报告质量（STROBE）声明：观察性研究报告规范. Available: https://www.equator-network.org/wp-content/uploads/2015/10/STROBE-Chinese.pdf

  4. Hugh MacPherson, Douglas G Altman, Richard Hammerschlag, 李幼平, 吴泰相, Adrian White, David Moher. 针刺临床试验干预措施报告标准的修订：CONSORT声明的扩展[J]. 中西医结合学报, 2010, 8(09): 804-818.

  5. Kenneth F Schulz, Douglas G Altman, David Moher, 周庆辉, 卞兆祥, 刘建平. CONSORT 2010声明：报告平行对照随机临床试验指南的更新[J]. 中西医结合学报, 2010, 8(07): 604-612.

  6. 陈珏璇, 段玉婷, 卞兆祥, 张弛, 陈耀龙. 更好地报告干预措施：描述干预措施的模板和报告规范[J]. 中国循证医学杂志, 2020, 20(12): 1439-1448.

  7. 黄耀连, 刘凡, 段玉婷, 卞兆祥, 张弛, 陈耀龙. 社会及心理干预措施随机试验报告规范：CONSORT-SPI 2018扩展版[J]. 中国循证医学杂志, 2020, 20(12): 1449-1457.

  8. 黄耀连, 刘凡, 段玉婷, 卞兆祥, 张弛, 陈耀龙. CONSORT-SPI 2018的解释与说明：社会和心理干预措施试验报告规范[J]. 中国循证医学杂志, 2020, 20(12): 1458-1470.

  9. 田然, 林伟青, 段玉婷, 卞兆祥, 张弛, 商洪才. 草药干预措施随机对照试验报告：CONSORT扩展声明[J]. 中国循证医学杂志, 2021, 21(01): 97-99.

  10. 田然, 林伟青, 段玉婷, 商洪才, 张弛, 卞兆祥. 报告草药干预措施随机对照试验的建议：解释和说明[J]. 中国循证医学杂志, 2021, 21(01): 100-110.

  11. 赵晨, 付姝菲, 段玉婷, 张弛, 商洪才, 卞兆祥. CONSORT声明：在牙科矫正临床试验中的扩展与应用[J]. 中国循证医学杂志, 2021, 21(02): 219-230.

  12. 王家莹, 付姝菲, 段玉婷, 张弛, 商洪才, 卞兆祥. 卫生保健仿真研究报告规范：基于CONSORT和STROBE声明的扩展[J]. 中国循证医学杂志, 2021, 21(02): 241-248.

  13. 魏旭煦, 刘岩, 胡嘉元, 蒋寅, 商洪才, 张弛, 段玉婷, 卞兆祥. 多臂平行对照随机临床试验报告规范：CONSORT 2010声明扩展版[J]. 中国循证医学杂志, 2021, 21(02): 231-240.

  14. 蒋寅, 刘岩, 商洪才, 张弛, 段玉婷, 卞兆祥, Eldridge SM, Chan CL, Campbell MJ. CONSORT 2010声明：针对随机先导性和可行性试验的扩展[J]. 中国循证医学杂志, 2021, 21(03): 313-337.

  15. 胡嘉元, 李江, 翟静波, 李博, 田金徽, 马彬, 杨克虎, 代敏, 田贵华, 商洪才, 张弛, 段玉婷, 卞兆祥. 中医药单病例随机对照试验报告规范（中医药CENT）：CENT声明的扩展、说明与详述[J]. 中国循证医学杂志, 2021, 21(03): 338-346.

  16. 陈泽, 陈珏璇, 段玉婷, 张弛, 陈耀龙, 卞兆祥, Calvert M, Blazeby J, Altman DG. 随机对照试验中的患者报告结局：CONSORT PRO扩展版[J]. 中国循证医学杂志, 2021, 21(03): 347-354.